TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03854383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide mononitrate
Description: Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Used intravaginally to ripe the cevix in induction of labor

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Misoprostol
Description: Used intravaginally to ripe the cevix in induction of labor
Study: NCT01623388

Intervention type: PROCEDURE
Intervention: Oral glucose tolerance test for Phase I
Description: Oral glucose tolerance test for Diabetic patients in phase I
Study: NCT00435084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APO866
Study: NCT00618878

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: twice a week for 26 treatments in total

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Therapy
Description: twice a week for a total of 26 treatments
Study: NCT04071678

Intervention type: BEHAVIORAL
Intervention: Careful examination during endoscopic procedures to identify lesions
Description: When the AI model alarms, check carefully to confirm the lesion

Intervention type: BEHAVIORAL
Intervention: Careful examination during endoscopic procedures to identify lesions
Description: When the AI model alarms, check carefully to confirm the lesion

Intervention type: BEHAVIORAL
Intervention: Careful examination during endoscopic procedures to identify lesions
Description: When the AI model alarms, check carefully to confirm the lesion
Study: NCT02728297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staged ETS
Description: Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
Study: NCT04058886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-delivered Mindfulness
Description: The telephone-delivered mindfulness training intervention that will incorporate the following elements: 1) training for primary caregivers (CG) and their caregiving partner (CP) in a telephone-based mindfulness training intervention; 2) groups of up to eight participants (four CG-CP pairs) plus an instructor, on a shared telephone line; and 3) training in a 8-week, modified MBSR program, which places additional emphasis on training in the following: a) mindful experiencing, including mindfulness of feelings and body sensations; b) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking; and c) mindful compassion for self and others. Additionally, homework assignments will involve listening to exercises on a dial-in telephone line; and assignments for CG-CP dyads (e.g. mindful listening and communication practices) as well as CG mindfulness practices in the presence of care recipients (e.g. mindful eating, and mindful listening).
Study: NCT01667874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collatamp G sponge
Description: Collatamp G is an antibiotic impregnated sponge
Study: NCT02795091

Intervention type: OTHER
Group type: OTHER
Intervention: manual cleaning
Description: manual clean the rag and floor towel

Intervention type: DEVICE
Group type: OTHER
Intervention: machine clean
Description: machine clean the rag and floor towel
Study: NCT04078984

Intervention type: OTHER
Intervention: Experimental
Description: * Daily measures of End Inspiratory Pressure with respiratory synchronisation optimised by use of EAdi~* Daily spontaneous breathing trial using low levels of pressure support~* Pplat, Respiratory System Compliance, Driving Pressure, PEEP, Tidal Volume will be monitored daily as well as clinical and other routine ventilatory data. Data concerning initial severity of ARDS, and duration of ARDS, controlled mechanical ventilation, sedation and neuromuscular blockade and date of first spontaneous breathing trial will be collected. A weaning test will be conducted daily.
Study: NCT00609739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients \>40 kg with normal renal function (creatinine \<1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 3000 mg/m\^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m\^2/day) on days -9 through -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Patients with absolute neutrophil count (ANC) \<0.2 x 10\^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10\^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m\^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m\^2 IV on days +3, +6, and +11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: 10 mg/m\^2 over 30 minutes intravenously (IV) on days -9 through -7.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 \>10\^8/kg recipient weight. Infused on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-Retinoic acid
Description: Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m\^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
Study: NCT01142427

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01772576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reliance 4-Front lead implantation
Description: The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
Study: NCT03746041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abaloparatide
Description: In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
Study: NCT01978223

Intervention type: PROCEDURE
Intervention: Stool sample collection
Description: Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.

Intervention type: PROCEDURE
Intervention: Stool sample collection
Description: Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
Study: NCT02999633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form:pills Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Pharmaceutical form:pills Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT05997706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular biopsy
Description: Testicular biopsy is a clinical procedure for extraction of testicular tissue
Study: NCT01032499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytetracycline, taro elixir
Description: comparison of treatment efficacy between oxytetracycline and taro elixir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taro Elixir
Description: Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
Study: NCT04397419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Bull Energy Drink
Description: The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Still water
Description: The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml
Study: NCT00961194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup.
Study: NCT03505528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin-bound paclitaxel
Description: Abraxane is administered intravenous at a constant dose of 100mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenelzine Sulfate
Description: Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
Study: NCT02661074

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish.

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish.

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish.
Study: NCT00504894

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental
Description: A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
Study: NCT02492282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop propofol and remifentanil system by Bispectral Index

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-Loop propofol and remifentanil by Target Controlled Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study: NCT04858282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application (BC-SDM)
Description: The mobile application (BC-SDM)includes four functions to support SDM activity: Understanding breast cancer, Surgical approach, Choose the right breast cancer knowledge, and Let's make a decision for myself. Patients first read the information in Understanding breast cancer and Surgical approach to receive a tailored education in breast cancer
Study: NCT02841241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol infusion
Study: NCT01257022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Description: There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
Study: NCT02262962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Redesigned Well-Child Care
Description: The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
Study: NCT04328272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine 200 Mg Oral Tablet
Description: Hydroxychloroquine administered orally with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 Mg Oral Tablet
Description: Hydroxychloroquine administered orally with water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 500Mg Oral Tablet
Description: Azithromycin administered orally with water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose tablets
Description: administered orally with water
Study: NCT03892135

Intervention type: OTHER
Intervention: Interviews with parents of children with juvenile idiopathic arthritis
Description: Interviews with parents of children with juvenile idiopathic arthritis

Intervention type: OTHER
Intervention: Interviews with children with juvenile idiopathic arthritis
Description: Interviews with children with juvenile idiopathic arthritis

Intervention type: OTHER
Intervention: Interviews with Physicians
Description: Interviews with Physicians
Study: NCT00709410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBS-WC vaccine
Description: 1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
Study: NCT00768144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study: NCT01035944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemCon Dressings and HemCon ChitoGauze; chitosan-based.
Description: Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemCon Dressings and HemCon ChitoGauze; chitosan-based.
Description: Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
Study: NCT03936972

Intervention type: PROCEDURE
Intervention: ilizarov circular frame and uni-planarexternal fixator
Description: both are types of external fixators, but one is circular frame and other is uni-planar frame

Intervention type: PROCEDURE
Intervention: ilizarov circular frame and uni-planarexternal fixator
Description: both are types of external fixators, but one is circular frame and other is uni-planar frame
Study: NCT05122429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health Treatment
Description: Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health Treatment
Description: Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health Treatment
Description: Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
Study: NCT01500304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive inguinal lymph node dissection
Description: Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
Study: NCT01211821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: Tablets, Oral, 200 mg, once, 1 day

Intervention type: DRUG
Group type: OTHER
Intervention: metoprolol
Description: Tablets, Oral, 200 mg, once, 1 day
Study: NCT01035944

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze and saline dressings.
Description: Control for both settings will be gauze and saline dressings.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze and saline dressings.
Description: Control for both settings will be gauze and saline dressings.
Study: NCT04089059

Intervention type: DEVICE
Group type: OTHER
Intervention: Cordella™ Pulmonary Artery Sensor System
Description: The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)
Study: NCT01211821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914392
Description: Tablets, Oral, 60 mg, once daily, 7 days
Study: NCT04224506

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study: NCT03312205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CAR-T cells
Description: Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
Study: NCT00857974

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.